Accessibility Menu
Monte Rosa Therapeutics logo

Monte Rosa Therapeutics(NASDAQ) GLUE

Market Cap$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-26%
5 Year-58%
1 Year+234%
1 Month-37%
Premium Feature
Moneyball Superscore
73/100
$14.78
-6.28%
-0.99Today
Monte Rosa Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 14.782026-08-20
Monte Rosa Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.69%USD 15.842026-08-13
1 month-37.45%USD 23.632026-07-21
3 month-21.42%USD 18.812026-05-22
Year to date-5.74%USD 15.682025-12-31
1 year+233.63%USD 4.432025-08-20
3 year+136.86%USD 6.242023-08-21
5 year-58.06%USD 35.242021-08-20
Since inception-25.54%USD 21.182021-06-24

Monte Rosa Therapeutics Financials at a Glance

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$28.73M

Net Income (TTM)

-$161.12M

EPS (TTM)

-$1.91

P/E Ratio

-7.76

Dividend

$0.00

Beta (Volatility)

1.65 (High)

Price

$14.78

Volume

1

Open

$15.62

Previous Close

$14.78

Daily Range

$14.72 - $15.90

52-Week Range

$4.52 - $25.77

Estimated Earnings Date

Nov 5, 2026

GLUE News

SellAlert-Red.png

After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?

Jonathan PoncianoJun 29, 2026
SellAlert-Purple.png

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Jonathan PoncianoApr 21, 2026
Foolcom-Featured.png

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

Motley Fool Markets TeamAug 7, 2025

GLUE: Motley Fool Moneyball Superscore

73

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc. makes medicines that destroy harmful proteins. These drugs help people fighting cancer and immune disorders. The company uses the body's natural systems to heal.

A Pipeline for Precision

  • GSPT1 (MRT-2359): Oral drug designed to treat Myc-driven cancers by destroying specific proteins.
  • VAV1 (MRT-6160): Treatment for autoimmune disorders currently licensed to Novartis for development.
  • NEK7: Research program targeting inflammatory conditions such as Crohn's disease and diabetes.
  • CDK2: Potential therapy for ovarian, uterine, and breast cancers.

Major Partnerships and Capital

  • Partnered with Roche in October 2023 to identify degraders for cancer and neurological diseases.
  • Signed a license agreement with Novartis in October 2024 for the VAV1 program.
  • Entered a second Novartis agreement in September 2025 for immunology research.
  • Raised $323.8 million in net proceeds through a public stock offering in January 2026.

The Secret to Molecular Glue

Monte Rosa uses its QuEEN discovery engine to design drugs called molecular glue degraders. These small molecules use the body's natural disposal system to eliminate proteins that cause cancer and other diseases.

Tracking the Numbers

  • Net loss was $87.9 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $626.0 million as of June 30, 2026.
  • Collaboration revenue was $13.2 million for the six-month period ended June 30, 2026.
  • Research and development expenses were $92.0 million for the six-month period ended June 30, 2026.
  • The company expects its current cash and marketable securities to support operations into 2029.

Bottom Line

Monte Rosa has evolved from a startup into a clinical-stage biotechnology firm with multiple global pharmaceutical partners. Its proprietary engine and focus on protein degradation position it to address complex diseases using the body's own biological tools.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

150

CEO

Markus Warmuth, MD

Website

www.monterosatx.com

Headquarters

Boston, MA 02118, US

GLUE Financials

Key Financial Metrics (TTM)

Gross Margin

92.94%

Operating Margin

-633.04%

Net Income Margin

-560.85%

Return on Equity

-43.31%

Return on Capital

-19.91%

Return on Assets

-23.15%

Earnings Yield

-12.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

85.31M

Volume

1

Avg. Volume

1.40M

Financials (TTM)

Gross Profit

$26.70M

Operating Income

-$181.85M

EBITDA

-$155.85M

Operating Cash Flow

-$61.44M

Capital Expenditure

-$9.88M

Free Cash Flow

-$71.32M

Cash & ST Invst.

$621.10M

Total Debt

$37.99M

Monte Rosa Therapeutics Performance Analysis

Monte Rosa Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 75,622,000N/A
20252025-12-31USD 123,672,00063.5%
Monte Rosa Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-45.0%
Q42025-12-31-78.2%
Q12026-03-3151.4%
Q22026-06-30113.0%
Monte Rosa Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.3044.6%
20232023-12-31USD -2.6314.6%
20242024-12-31USD -0.98-62.7%
20252025-12-31USD -0.47-52.7%
Monte Rosa Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-120.0%
Q42025-12-31-59.1%
Q12026-03-3124.3%
Q22026-06-303.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$8.97M

-61.3%

Gross Profit

$8.97M

-61.3%

Gross Margin

100.00%

N/A

Market Cap

$1.26BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.29M

N/A

Employees

173

N/A

Net Income

-$43.40M

-253.0%

EBITDA

-$41.28M

-360.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$621.10M

+113.7%

Total Debt

$37.99M

-7.6%

Accounts Receivable

$9.84M

+315.2%

Inventory

$0.00

N/A

Long Term Debt

$33.36M

-9.9%

Short Term Debt

$4.63M

+13.1%

Return on Assets

-23.15%

N/A

Return on Invested Capital

-28.90%

N/A

Free Cash Flow

-$88.07M

-141.9%

Operating Cash Flow

-$81.48M

-134.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
REPLReplimune Group, Inc.
$14.05-5.13%
MGTXMeiraGTx Holdings plc
$14.54-2.87%
AVBPArriVent BioPharma, Inc.
$29.18-2.80%
GERNGeron Corporation
$1.55-2.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$41.20+0.06%
MSTRStrategy
$112.39+0.08%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$46.25-0.02%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$122.21+0.01%

Questions About GLUE

What is the current price of Monte Rosa Therapeutics?

Monte Rosa Therapeutics is trading at $14.78 per share.

What is the 52-week range for Monte Rosa Therapeutics?

Over the past 52 weeks, Monte Rosa Therapeutics has traded between $4.52 and $25.77.

How much debt does Monte Rosa Therapeutics have?

As of the most recent reporting period, Monte Rosa Therapeutics reported total debt of $37.99M.

How much cash does Monte Rosa Therapeutics have on hand?

Monte Rosa Therapeutics reported $90.10M in cash and cash equivalents in its most recent financial results.

What is Monte Rosa Therapeutics’s dividend yield?

Monte Rosa Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services